Novel Drug Approvals for 2023- (1 to 10)
Drug Name:
Novel Drug Approvals for 2023- (1 to 10)
List Of Brands:
Indication Type Description:
Pharmacology/ Pharmacokinetics
Drug Interaction:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
1.LEGEMBI Lecanemab-irmb 1/6/2023 To Alzheimer's disease
Manufactured by: Eisai Inc. Nutley, NJ 07110 U.S. License No. 1862 LEQEMBITM is a trademark of Eisai R&D Management Co., Ltd. © XXXX Eisai Inc. and Biogen
Indication:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
2. BRENZAVVY Bexagliflozin 1/20/2023 To improve glycemic control in adults with type 2 diabetes mellitus type 2 diabetes mellitus as an adjunct to diet and excercise
Adverse Reaction:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
3. JAYPIRCA Pirtobrutinib 1/27/2023 To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor
Contra-Indications:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
4. ORSERDU Elacestrant 1/27/2023 To treat receptor positive, human epidermal growth receptor-2-negative ESRI-1 - mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy
Dosages/ Overdosage Etc:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
5. JESDUVROQ Daprodustat 2/1/2023 To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months
Other Information:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
6. LAMZEDE Velmanase alfa-tycv 2/1/2023 To treat non-central nervous system manifestations of alpha- mannosidosis
Patient Information:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
7. FILSPARI Sparsentan 2/17/23 To reduce proteinuria in adults with primary immunoglobulin A nephropathy at risk of rapid disease progression
Pharmacology/ Pharmacokinetics:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
8. SKYCLARYs Omaveloxolone 2/28/2023 To treat Friedrich's ataxia
Interaction with Food:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
9. ZAVZPRET Zavegepant 3/9/2023 To treat migraine
Pregnancy and lactation:
No. Drug Name Active Ingred. Apprvl Date FDA Approved use on approved date
M- Manufacturer D-Distributor
10. DATBLUE Trofintide 2/10/2023 To treat Rett syndrome
